Menu
Back to Journals » Biologics: Targets and Therapy » Volume 13 » default
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (502)
- Volume 18, 2024 (6)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 13, 2019
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
Chandra A, Kanth R, Thareja S
Biologics: Targets and Therapy 2019, 13:191-200
Published Date: 25 November 2019
Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats
Samsu N, Soeharto S, Rifai M, Rudijanto A
Biologics: Targets and Therapy 2019, 13:179-190
Published Date: 30 August 2019
Remicade® (infliximab): 20 years of contributions to science and medicine
Melsheimer R, Geldhof A, Apaolaza I, Schaible T
Biologics: Targets and Therapy 2019, 13:139-178
Published Date: 30 July 2019
Clinical utility of ramucirumab in non-small-cell lung cancer
Uprety D
Biologics: Targets and Therapy 2019, 13:133-137
Published Date: 22 July 2019
Therapeutic drug monitoring of biologics in psoriasis
Liau MM, Oon HH
Biologics: Targets and Therapy 2019, 13:127-132
Published Date: 5 July 2019
Antitumor and antibacterial properties of virally encoded cationic sequences
Colle JH, Périchon B, Garcia A
Biologics: Targets and Therapy 2019, 13:117-126
Published Date: 25 June 2019
Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab
Lerkvaleekul B, Treepongkaruna S, Ruangwattanapaisarn N, Treesit T, Vilaiyuk S
Biologics: Targets and Therapy 2019, 13:111-116
Published Date: 14 June 2019
TRIP6 functions as a potential oncogene and facilitated proliferation and metastasis of gastric cancer
Zhu L, Xu X, Tang Y, Zhu X
Biologics: Targets and Therapy 2019, 13:101-110
Published Date: 11 June 2019
Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
Salehzadeh F, Mohammadikebar Y, Enteshary A, Ghanbarpour O, Mirzarahimi M
Biologics: Targets and Therapy 2019, 13:97-99
Published Date: 27 May 2019
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
Caminati M, Bagnasco D, Vaia R, Senna G
Biologics: Targets and Therapy 2019, 13:89-95
Published Date: 22 May 2019
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
Smirnova LM, Vertieva EY, Olisova OY, Anpilogova EM
Biologics: Targets and Therapy 2019, 13:83-87
Published Date: 20 May 2019
Dupilumab side effect in a patient with atopic dermatitis: a case report study
Albader SS, Alharbi AA, Alenezi RF, Alsaif FM
Biologics: Targets and Therapy 2019, 13:79-82
Published Date: 13 May 2019
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
Lim SYD, Oon HH
Biologics: Targets and Therapy 2019, 13:53-78
Published Date: 13 May 2019
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Cruz E, Kayser V
Biologics: Targets and Therapy 2019, 13:33-51
Published Date: 1 May 2019
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
Viscido A, Papi C, Latella G, Frieri G
Biologics: Targets and Therapy 2019, 13:23-31
Published Date: 9 April 2019
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M
Biologics: Targets and Therapy 2019, 13:13-21
Published Date: 3 January 2019
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Keyel ME, Reynolds CP
Biologics: Targets and Therapy 2019, 13:1-12
Published Date: 21 December 2018